Cimetidine Biowaivers

This study is currently recruiting participants.
Verified July 2011 by University of Maryland
Sponsor:
Collaborator:
Food and Drug Administration (FDA)
Information provided by:
University of Maryland
ClinicalTrials.gov Identifier:
NCT01256879
First received: November 15, 2010
Last updated: July 31, 2011
Last verified: July 2011

November 15, 2010
July 31, 2011
March 2011
August 2011   (final data collection date for primary outcome measure)
amount of drug in blood [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
Blood samples will be collected to measure level of cimetidine.
Same as current
Complete list of historical versions of study NCT01256879 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cimetidine Biowaivers
Evaluation of Excipient Effects on Biopharmaceuticals Classification System (BCS) Class 3 Drug Cimetidine

The purpose of this research is to see if non-drug ingredients in capsules and oral solutions affect how well drugs are absorbed. This is called "bioequivalence." Medications taken by mouth, such as capsules and solutions, need to be absorbed into the body in order to do any good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the capsules and solutions can impact how much drug is absorbed into the body. This is called "bioINequivalence." Capsules and solutions in this research contain the drug cimetidine. This drug is being used since it has high water solubility (can dissolve in water) and low ability to be absorbed.

The investigators anticipate that common excipients do not cause bioINequivalence. 1) The hypothesize is that commonly used excipients in oral medications change the rate or extent of Class 3 drug absorption and result in bioINequivalence. 2) Alternative hypothesis is that commonly used excipients in oral medications do not change the rate or extent of Class 3 drug absorption and do not result in bioINequivalence.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Healthy
Drug: cimetidine
cimetidine 200mg total dose (single dose) per arm
  • Experimental: formulation 1
    cimetidine capsule with sodium lauryl sulfate (SLS), a type of filler
    Intervention: Drug: cimetidine
  • Experimental: formulation 2
    cimetidine capsule with sodium starch glycolate (SSG) - a type of filler
    Intervention: Drug: cimetidine
  • Active Comparator: formulation 3
    commercial cimetidine solution
    Intervention: Drug: cimetidine
  • Experimental: formulation 4
    experimental (non-commercial) cimetidine solution
    Intervention: Drug: cimetidine
Rege BD, Yu LX, Hussain AS, Polli JE. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci. 2001 Nov;90(11):1776-86.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
24
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or Female
  • Age 18-55
  • Healthy volunteers: Subjects in good health, as determined by screening evaluation that is not greater than 30 days before the first drug study visit
  • Willing to avoid caffeine containing products 24 hours prior to and day of study visits
  • Willing to stop all over the counter medications for 24 hours prior to and during study visits
  • Able to provide informed consent

Exclusion Criteria:

  • Presence of significant medical disease (including cardiovascular, pulmonary, hematologic, endocrine, immunologic, neurologic, gastrointestinal or psychiatric)
  • Presence of hepatic, renal disease
  • Pregnant women, breast feeding or trying to become pregnant
  • Excessive alcohol use (i.e. current physical, behavioral, or personal manifestations related to the abuse or dependency on alcohol)
  • Routine use (i.e. daily or weekly) prescription medication except birth control pills
  • Routine use (i.e. daily or weekly) use of acid blockers, antacids, anti-diarrhea, stimulants, appetite suppressants, or anti nausea medication or other drugs that modulate gastrointestinal function
  • Currently taking cimetidine or medication known to interact with cimetidine
  • Allergic to cimetidine
  • Undergoing therapy for solid tumor or blood malignancy
  • Any condition in which in the opinion of the PI or medical physician would increase risk to the subject or interfere with the integrity of the study.
Both
18 Years to 55 Years
Yes
Contact: James Polli 410-706-8292 jpolli@rx.umaryland.edu
United States
 
NCT01256879
HP-00046139, HHSF2232000910020C
Yes
James E Polli, University of Maryland
University of Maryland
Food and Drug Administration (FDA)
Principal Investigator: James Polli, PhD University of Maryland
University of Maryland
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP